Sagent Pharmaceuticals (SGNT) Misses Q2 EPS by 6c

Go back to Sagent Pharmaceuticals (SGNT) Misses Q2 EPS by 6c

Sagent Pharmaceuticals Reports Second Quarter 2015 Financial Results

August 4, 2015 7:00 AM EDT

Company to evaluate strategic alternatives for Sagent (China) Pharmaceuticals

Company modifies earnings guidance for 2015

SCHAUMBURG, Ill., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced financial results for the quarter ended June 30, 2015.

Second Quarter 2015 Highlights

Revenue increased 12% to $77.3 million driven primarily by the October 1, 2014 acquisition of Omega Laboratories Limited ("Omega"); Reported gross profit declined 18% to $18.4 million, or 23.8% of net revenue;... More

Sagent Pharmaceuticals Board Appoints Allan Oberman as Chief Executive Officer

August 3, 2015 4:25 PM EDT

SCHAUMBURG, Ill., Aug. 3, 2015 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) a leader of specialty pharmaceutical products with a specific emphasis on the injectables market, today announced that its Board of Directors has named Allan Oberman as Chief Executive Officer and a member of the Board of Directors, effective immediately upon receipt of a US work visa.

"Allan is a proven leader with impeccable credentials and strategic instincts that will serve Sagent well as we enter our next phase of growth," said Robert J. Flanagan, Chairman of Sagent's Board of Directors. "Allan... More